Oncternal Therapeutics 以 $3M 的预付款和高达 $65M 的里程碑将其药物项目出售给 Ho'ola Therapeutics。 Oncternal Therapeutics sold its drug programs to Ho'ola Therapeutics for $3M upfront and up to $65M in milestones.

Oncternal Therapeutics 以 300 万美元的预付款将其 zilovertamab 和 ONCT-808 药物项目出售给 Ho'ola Therapeutics，未来里程碑付款可能高达 6500 万美元。 Oncternal Therapeutics sold its zilovertamab and ONCT-808 drug programs to Ho'ola Therapeutics for an upfront payment of $3 million, with potential for up to $65 million in future milestone payments. Oncternal的首席执行官Craig R. Jalbert将监督公司业务的收尾工作。 Oncternal's CEO, Craig R. Jalbert, will oversee the wind-down of the company's operations. 交易存在风险,包括Ho'ola开发和批准产品的能力。 The transaction is subject to risks, including Ho'ola's ability to develop and approve the products.